The Shotlee Journal
Browse Shotlee articles about Ozempic.
Showing 9 / 1090 Ozempic articles
Eli Lilly has declined to list its highly effective GLP-1/GIP agonist, Mounjaro (tirzepatide), on the Pharmaceutical Benefits Scheme (PBS) in Australia, citing disagreements over pricing. This decision has significant implications for patients seeking access to this crucial medication for type 2 diabetes and increasingly, for weight management.
The world of biohacking is increasingly embracing peptides, but what's the reality behind the hype? This article delves into the science, the risks of unregulated substances, and the potential impact of regulatory changes on access to these compounds.
Dr. Reddy's Laboratories has announced a significant milestone in its pursuit of bringing its semaglutide injection to the Canadian market, having received Drug Identification Numbers (DINs) from Health Canada. This development signals progress in the regulatory review process and underscores the company's commitment to expanding access to this important medication.
While GLP-1 medications like Ozempic and Mounjaro offer significant weight loss potential, many individuals experience plateaus. Discover how a simple, affordable supplement – psyllium husk – can amplify their effects, improve satiety, and support long-term weight management.
Significant weight loss, often achieved with medications like GLP-1 agonists, can bring about transformative health benefits but also raises questions about changes in appearance. This article delves into the phenomenon of 'Mounjaro face,' discusses how to approach sensitive conversations about appearance with friends and family, and offers practical advice for maintaining well-being during and after weight loss.
Athletes are increasingly curious about peptides for performance enhancement and recovery. This article delves into the scientific literature to separate the hype from the reality, examining the evidence for popular peptides and their potential risks.
While GLP-1 medications are celebrated for weight loss and reduced food noise, some users report emotional flattening. This article delves into the 'Ozempic personality' phenomenon, its potential causes, and expert perspectives on managing these psychological shifts.
As brand-name GLP-1 medications such as Ozempic and Wegovy become increasingly sought after for weight loss and diabetes management, many Canadians face significant cost barriers. The anticipation surrounding the approval of generic semaglutide offers a beacon of hope for improved accessibility and affordability. This article delves into the current landscape, patient stories, and expert insights on the journey towards more accessible peptide therapies.
New research suggests an outpatient endoscopic procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Wegovy and Mounjaro.
